| Cangrelor | percutaneous coronary intervention, in stable and unstable ACS | vs clopidogrel up front | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 1.04 [0.88 1.24] | p=1.00 | 0 | 7754 | 1 | CHAMPION-PCI, | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 0.40 [0.12 1.27] | p=1.00 | 0 | 7754 | 1 | CHAMPION-PCI, | | stroke (fatal and non fatal) | 0.85 [0.29 2.54] | p=1.00 | 0 | 7754 | 1 | CHAMPION-PCI, | | MACE | 0.67 [0.40 1.14] | p=1.00 | 0 | 7754 | 1 | CHAMPION-PCI, | | All cause death | 1.59 [0.52 4.87] | p=1.00 | 0 | 7754 | 1 | CHAMPION-PCI, | | Major bleeding | no data | | net benefit | no data | | stent thrombosis | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| CHAMPION-PCI, 2009 | cangrelor up front (cangrelor administered before percutaneous coronary intervention and followed by clopidogrel) | clopidogrel up front (clopidogrel followed by placebo) | high risk patients requiring PCI |
| |
